Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Experimental RNAi02:15

Experimental RNAi

8.4K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.4K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

773
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
773
RNA Interference01:23

RNA Interference

28.7K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
28.7K
RNA Interference01:23

RNA Interference

7.9K
7.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-Temperature-Induced Antitumor Effects of Amplitude-Modulated Radiofrequency: Molecular and Functional Synergies with Radiotherapy.

Cancers·2026
Same author

The Regulatory Interplay of the Colorectal Cancer Biomarkers MACC1 and IER2 and Its Impact on Metastatic Cancer Survival.

Biomolecules·2026
Same author

Prognostic impact of TROP2 in adenocarcinoma of the esophageal junction and stomach.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same author

MACC1 Expression in Colorectal Cancer Is Upregulated by Loss of Epigenetic Repression Under Oxidative Stress Condition.

Cell biochemistry and function·2025
Same author

Novel High-Throughput Screen Identified S100A4 Inhibitors for Anti-Metastatic Therapy.

International journal of biological sciences·2025
Same author

TransTACs: novel heterobispecific antibodies for targeted protein degradation in cancer therapy.

Signal transduction and targeted therapy·2024

Related Experiment Video

Updated: Apr 10, 2026

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
05:39

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Published on: April 5, 2024

1.4K

RNA Interference for Antimetastatic Therapy.

Mathias Dahlmann1, Ulrike Stein

  • 1Translational Oncology of Solid Tumors, Experimental and Clinical Research Center, Charité University Medicine Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany, dahlmann@mdc-berlin.de.

Methods in Molecular Biology (Clifton, N.J.)
|June 15, 2015
PubMed
Summary

RNA interference effectively suppresses cancer metastasis. Systemic shRNA plasmid delivery reduced S100A4 expression by 30%, leading to a 70% decrease in liver metastases in mice.

More Related Videos

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

1.4K
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

858

Related Experiment Videos

Last Updated: Apr 10, 2026

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
05:39

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Published on: April 5, 2024

1.4K
Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

1.4K
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

858

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Background:

  • RNA interference (RNAi) is a promising cancer treatment strategy.
  • Effective delivery and sustained presence of interfering molecules are crucial for RNAi therapy.
  • Targeting metastasis-driving genes is key to preventing cancer spread.

Purpose of the Study:

  • To describe a method for systemic application of shRNA expression plasmid for cancer therapy.
  • To evaluate the efficacy of targeting S100A4 in reducing colorectal cancer metastasis.
  • To demonstrate sustained reduction of target gene expression in primary tumors.

Main Methods:

  • Systemic administration of shRNA expression plasmid via tail vein injection in xenograft mice.
  • Selection of S100A4 as a metastasis-driving target gene.
  • In vivo imaging to monitor tumor growth and metastasis formation.
  • End point analysis including metastatic burden scoring and gene expression quantification.

Main Results:

  • Sustained reduction of target gene expression in the primary tumor.
  • Restricted formation of distant colorectal cancer metastases.
  • Average S100A4 expression reduced by 30% in tumor tissues.
  • Significant 70% decrease in liver metastases.

Conclusions:

  • Systemic shRNA plasmid delivery is an effective method for cancer therapy.
  • Targeting S100A4 with RNAi can significantly inhibit colorectal cancer metastasis.
  • This approach offers a potential strategy for controlling metastatic disease.